7 October 2017 - Late last year Britain’s competition watchdog slapped a record £90m worth of fines on US drugs giant Pfizer, and British manufacturer Flynn, for jacking up the price of an anti-epilepsy pill by more than 2,000%.

To critics of big pharma, it was a clear and egregious example of “price gouging” – hiking the price of a product in a market you dominate in order to rake in big profits.

But for Pfizer and Flynn – who embark on an appeal against the decision later this month – it was a justified increase to ensure continued supply of a drug they claim had previously been loss-making.

Read The Telegraph article